Senlang Bio's BCMA-Targeted CAR-T Therapy SENL103 Granted Clinical Approval for Autoimmune Disease Treatment

2025Year8Month5Day，Senlangbio's SENL103 Autologous T-cell Injection Granted Clinical Trial Approval for Refractory Generalized Myasthenia Gravis (rgMG)

SENL103 Autologous T-cell Injection is aCAR-T cell therapy drugs targeting BCMA can "precisely target" tumors through genetically engineered T cells, specifically acting on the highly expressed BCMA in multiple myeloma cells., thereby exerting the therapeutic effect. Previously,The approved clinical indication is relapsed or refractory multiple myeloma (RRMM).

Senlangbio is a high-tech enterprise specializing in the research, production, and commercialization of cell therapy products. The company is committed to advancing the clinical application of cell therapy through leading technologies and innovative solutions, benefiting a wide range of patients.

Since its establishment in 2016, the company has been continuously growing and developing. It now owns a 14,000㎡ R&D and production base built in accordance with international standards, and has established a one-stopCell therapy drug research and development and industrialization platform, nanobody development and screening platform, mastering core technologies such as large-scale plasmid preparation, lentiviral vector preparation, and primary immune cell preparation, successfully establishing the full CAR-T industry chain in China.Senlangbio's CD7-targeted CAR-T product, developed for relapsed or refractory T-lymphoblastic lymphoma/leukemia, utilizes a unique "natural selection" technology platform. It does not require gene editing for CD7 and has demonstrated good safety and efficacy in IIT (Investigator-Initiated Trials).Relevant data have been published in the international authoritative journals *Blood* and *American Journal of Hematology*. This product is currently in Phase I clinical trials in China, and in August 2023, it was granted Orphan Drug Designation (ODD) by the U.S. FDA. Globally, no CD7-targeted CAR-T therapy has been approved for marketing yet. The company’s CD19-targeted CAR-T product for B-cell acute lymphoblastic leukemia is currently undergoing clinical trial research in China.

In order to allow everyone to learn and communicate with each other better,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。